A rough prognosis for the health care sector, as new reports about RFK Jr’s allies point to a major overhang for vaccine makers. How names like Pfizer, Morderna, and Sanofi will fare under the new administration, as the entire health space comes into focus. Plus One more rate decision before the new year… and with expectations of another cut, could the Fed’s easing cycle be nearing an end? How next week’s rate decision will impact markets going into year end.